Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
Life expectancy of at least 12 weeks
Adequate hematologic and end-organ function
Acute, clinically significant treatment-related toxicity from prior therapy must have resolved to Grade \</=1 prior to study entry
Left Ventricular Ejection Fraction (LVEF) \>/=50%
Locally tested, Human Epidermal Growth Factor Receptor 2 (HER2)-expressing BC
Locally advanced or metastatic BC that has relapsed or is refractory to established therapies
Adenocarcinoma of the stomach or GEJ with inoperable locally advanced or recurrent and/or metastatic disease, not amenable to curative therapy
HER2-expressing tumor (primary tumor or metastasis) as assessed by local lab testing
HER2-positive gastric/GEJ cancer must have received prior trastuzumab, cisplatin (or carboplatin or oxaliplatin or investigational platinum agent) and 5-fluorouracil (5-FU)/capecitabine
HER2-positive tumor (primary tumor or metastasis) as assessed by local (non-central) laboratory testing
Locally advanced, recurrent, or metastatic incurable malignancy that has progressed after at least one available standard therapy; or for whom standard therapy has proven to be ineffective or intolerable, or is considered inappropriate; or for whom a clinical trial of an investigational agent is a recognized standard of care; or for whom a clinical trial of an investigational agent is considered an acceptable treatment option
You may not be if
Pregnant or breastfeeding, or intending to become pregnant during the study or within 140 days after the last dose of runimotamab
Significant cardiopulmonary dysfunction
Known clinically significant liver disease
Positive for acute or chronic Hepatitis B virus (HBV) infection
Acute or chronic Hepatitis C virus (HCV) infection
Human Immunodeficiency Virus (HIV) seropositivity
Poorly controlled Type 2 diabetes mellitus
History of ventricular dysrhythmias or risk factors for ventricular dysrhythmias
Current treatment with medications that are well known to prolong the Q-wave/T-wave (QT) interval
Known clinically significant liver disease
Primary central nervous system (CNS) malignancy, untreated CNS metastases, or active CNS metastases (progressing or requiring corticosteroids for symptomatic control)
Leptomeningeal disease
Spinal cord compression that has not definitively treated with surgery and/or radiation
History of autoimmune disease
Prior allogeneic stem cell or solid organ transplantation
Clareo Health | A Study of Runimotamab in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers
